Skip to main content
OpenTrials
Completed

NCT Number: NCT01616121

Preemptive Lung Impedance-Guided Therapy in Evolving Acute Heart Failure in Acute Myocardial Infarction Patients

It is well-known that 20-25% of patients hospitalized for acute myocardial infarction will develop acute heart failure during their hospitalization. Currently, the investigators have no reliable parameter for prediction of evolving acute heart failure in such a group of patients. As a result, the investigators have no way of preventing acute heart failure. Treatment of these patients only begins after appearance of clinical signs of acute heart failure. Lung impedance monitoring may be a good non-invasive parameter for prediction of evolving acute heart failure. This study will attempt to address whether preemptive lung impedance-guided therapy may prevent the development of overt acute heart failure and improve their clinical outcome.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Heart Failure Cardiovascular Diseases Heart Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Hillel Yaffe Medical Center

Hadera, 38100, Israel

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients hospitalized in the ICCU for acute myocardial infarction and developing acute heart failure

Exclusion criteria

  • Patients with acute myocardial infarction with clinical and radiological signs of acute heart failure at admission

Treatment and study plan

Usual treatment of patients with developing acute heart failure

Other

Lung Impedance-Guided Therapy

Device

Non-invasive lung impedance monitor (RSMM Company, Tel Aviv, Israel)

Primary outcomes

  1. Prevention of acute heart failure development in acute MI patients

    Time frame: Three years

Secondary outcomes

  1. Improvement of clinical outcome in patients with lung impedance-guided treatments

    Time frame: Three years

Sponsors and collaborators

Lead sponsor

Hillel Yaffe Medical Center

Other Gov

Registry information

Important dates

Study start
2002
Primary completion
2014
Study completion
2014
First posted
Jun 11, 2012
Registry last updated
Jun 19, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.